Ramucirumab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-RAMUCIRUMAB |
|---|---|
| Type | Drug |
| Aliases | CyramzaРамуцирумаб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-GASTRIC DIS-HCC DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | Anti-VEGFR2 IgG1 monoclonal antibody |
|---|---|
| Mechanism | Fully human IgG1 monoclonal antibody targeting the extracellular domain of VEGFR-2, blocking VEGF-A, -C, -D ligand binding and downstream pro-angiogenic + pro-survival signaling. Distinct from bevacizumab (anti-VEGF-A ligand). Approved across multiple solid tumors as second-line antiangiogenic. |
| Typical dosing | NSCLC (REVEL, with docetaxel): 10 mg/kg IV day 1 of each 21-day cycle. Gastric (RAINBOW, with paclitaxel): 8 mg/kg IV days 1, 15 of 28-day cycle. HCC (REACH-2, monotherapy AFP ≥400): 8 mg/kg IV q2 weeks. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Warnings
- Hemorrhage — including severe, sometimes fatal
- Gastrointestinal perforation
- Impaired wound healing
- Arterial thromboembolic events
Notes
REVEL trial (Garon 2014): in 2L NSCLC after platinum doublet, docetaxel + ramucirumab vs docetaxel improved mOS (10.5 vs 9.1 mo, HR 0.86). Modest absolute benefit; toxicity (hypertension, bleeding) is meaningful — careful patient selection. Hold ≥28 days before any major surgery; restart only after wound fully healed. Active hemoptysis or recent GI ulcer = contraindication.
Used By
Regimens
REG-DOCETAXEL-RAMUCIRUMAB- Docetaxel + Ramucirumab (REVEL) — 2L+ NSCLC post-platinum / post-ICIREG-PACLITAXEL-RAMUCIRUMAB-GASTRIC- Paclitaxel + Ramucirumab (RAINBOW) — 2L gastric/GEJREG-RAMUCIRUMAB-HCC- Ramucirumab (HCC, 2L high AFP)